Imdex

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Imdex

Property Description
Active ingredient Isosorbide Mononitrate (ISMN)
Form Oral Tablet (Extended/Controlled-Release)
Pharmacological class Nitrate Vasodilator, Anti-anginal Agent
General purpose Prevention of chest discomfort (Angina)
Origin Synthetic Organic Nitrate

Is Imdex an Organic Nitrate Vasodilator?

Imdex is a prescription-only medication whose active ingredient is Isosorbide Mononitrate (ISMN), a synthetic chemical substance. It is formally classified as an Anti-anginal Agent belonging to the Nitrate Vasodilator pharmacological class. This classification confirms its therapeutic role in conditions affecting the heart's blood supply. The chemical structure of Isosorbide Mononitrate is that of an organic nitrate, which is the major biologically active metabolite of isosorbide dinitrate. The distinct profile of ISMN is clinically recognized for its near-complete oral bioavailability, meaning it is readily absorbed and consistently delivered to the bloodstream, supporting its role in systemic management.

What is Isosorbide Mononitrate Used for Generally?

The general therapeutic purpose of the medicine is the consistent, long-term prophylaxis of chronic heart-related chest discomfort. Isosorbide Mononitrate acts as a Nitric Oxide Donor, which triggers the relaxation of vascular smooth muscle, predominantly in the veins, leading to vessel vasodilation. This action reduces the volume of blood returning to the heart, effectively lowering the heart's workload and oxygen demand. The drug’s role in decreasing the heart’s oxygen demand by causing systemic vasodilation highlights the core benefit of reducing the strain on the heart. This reduction in demand, known as preload reduction, is the core benefit utilized in the prevention of angina pectoris.

What Forms of Imdex are Available?

Imdex is supplied as an oral dosage form, specifically a tablet, and is a single-ingredient product. Most preparations are designed as extended-release (ER) or controlled-release formulations. The use of specialized excipients in these tablets allows for the controlled modulation of the Isosorbide Mononitrate release rate over time. This design is crucial because its sustained action is required for providing consistent, once-daily prophylactic coverage against anginal episodes, ensuring the heart benefits from reduced workload around the clock. The sustained action distinguishes it from immediate-release nitrate formulations.

Regulatory References

  1. Isosorbide Mononitrate Extended-Release Tablets Labeling

What side effects are possible with Imdex?

Possible Side Effects and Safety Information

The official safety characteristics of Isosorbide Mononitrate, the active ingredient in Imdex, are documented in government regulatory sources and are primarily related to its function as a nitrate vasodilator. The profile of adverse reactions is classified by frequency and grouped by organ system.


Adverse Reactions by Frequency

Classification Example Effects (from Official Labeling)
Very Common Headache (most frequent, sometimes leading to discontinuation)
Common Dizziness, Nausea, Flushing, Abdominal Pain, Diarrhea

Headache is reported to occur most frequently at the initiation of therapy and typically decreases in incidence after the first few days of treatment. Other common effects like dizziness and flushing stem from the medicine's vascular action.


Serious Safety Considerations

Serious adverse reactions are largely cardiovascular, including severe hypotension (low blood pressure), which can result in temporary loss of consciousness (syncope), and a potential slow heart rate (paradoxical bradycardia). The medication is strictly contraindicated for use with Phosphodiesterase-5 (PDE-5) inhibitors (e.g., sildenafil) and soluble Guanylate Cyclase Stimulators (e.g., riociguat) due to the risk of life-threatening blood pressure drops. Caution is specifically noted for older adults, who may be more susceptible to severe hypotension, and for patients with hypertrophic cardiomyopathy.


Regulatory Summary: The overall safety profile is defined by vascular side effects and absolute restrictions concerning drug-drug interactions, emphasizing the need for adherence to the regulatory constraints.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Imdex (Isosorbide Mononitrate) is officially documented to present with serious cardiovascular and neurological manifestations. Immediate medical attention must be sought if an overdose is suspected.

Documented Manifestations and Severe Outcomes

Overdose may result in a prompt and significant fall in blood pressure (severe hypotension), which is the principal life-threatening concern. Other documented effects include a persistent throbbing headache, syncope (fainting), nausea, vomiting, confusion, and visual disturbances. Life-threatening outcomes explicitly listed in regulatory information include profound CNS effects such as seizures, paralysis, and coma. A specific complication associated with nitrate toxicity is the potential development of Methemoglobinemia.

Regulatory Actions and Management

Regulators mandate that medical professionals be contacted immediately if severe signs or symptoms develop.

Area of Concern Official Regulatory Statement
Emergency Intervention Seek immediate medical attention. Avoid the use of epinephrine or other arterial vasoconstrictors, which are likely to do harm.
Supportive Management The focus is directed toward increasing central fluid volume using measures such as passive elevation of the legs or intravenous infusion of normal saline. Dialysis is ineffective.
Specific Treatment No specific antagonist is known for the drug’s vasodilator effects. Methylene Blue is the treatment specified for diagnosed Methemoglobinemia.
Monitoring Hospital observation for a minimum of 12 hours is required, along with continuous monitoring of blood pressure.

Therapeutic Uses of Imdex

What Imdex Treats: Main Uses and Benefits

The primary therapeutic focus of Imdex is applied across domains where additional symptomatic support is needed for conditions presenting with systemic or localized discomfort. The medicine is applied across domains where symptomatic management is appropriate for conditions where functional stability becomes affected, especially those characterized by periods of heightened symptoms. In therapeutic contexts involving similar agents, such products are commonly used to help with conditions presenting with systemic or localized discomfort.

Imdex is generally considered relevant for easing symptom clusters that may become intense or disruptive. It is considered relevant for managing symptom clusters that occur in conditions associated with acute or disruptive episodes, such as those linked to Type 2 diabetes mellitus, hypertension, dyslipidaemia, and obstructive sleep apnoea. Imdex provides support that helps ease the overall symptom burden and contributes to improved day-to-day comfort during symptomatic periods. It is applied when appropriate in situations requiring additional symptomatic assistance.

“Imdex may assist with maintaining a sense of stability when symptoms are more noticeable, and supports general well-being during symptomatic phases.”

Quick Fact: Relevant for Symptomatic Assistance

Imdex may help patients cope more steadily with symptom fluctuations.

Eligibility and Restrictions for Use

Who Can and Cannot Use Imdex? (Isosorbide Mononitrate)

Official regulatory documents define specific populations who are eligible, restricted, or absolutely prohibited from using Imdex. Eligibility is primarily established for adult patients receiving prophylaxis for chronic chest discomfort (angina pectoris).


Absolute Contraindications

Imdex is contraindicated (must not be used) in patients with a known hypersensitivity to any nitrate, including isosorbide mononitrate itself. The medicine is also strictly prohibited for individuals concurrently taking Phosphodiesterase type-5 (PDE-5) inhibitors (like sildenafil) or the sGC stimulator riociguat. Use is further contraindicated in states of severe hypotension (marked low blood pressure), cardiogenic shock, or acute circulatory failure.

Age and Condition Limitations

The safety and effectiveness have not been established in pediatric patients, meaning Imdex is not recommended for children. While older adults are generally eligible without routine dosage adjustment, caution is advised for those susceptible to low blood pressure or with severe renal or hepatic impairment.

Use Status

  • Pregnancy: Use is advised only if the potential benefit outweighs the potential risk.
  • Acute Episodes: The medicine is not indicated for use in aborting an acute anginal episode due to its slow onset of action.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile of Imdex (Isosorbide Mononitrate) is documented in regulatory prescribing information and is primarily defined by the risk of potentiated blood pressure lowering effects.

Contraindicated Combinations

Certain combinations are formally prohibited due to the risk of severe, life-threatening hypotension (extremely low blood pressure) and cardiovascular collapse. These combinations must not be used:

  • Phosphodiesterase type-5 (PDE5) Inhibitors: This includes medications such as Sildenafil, Tadalafil, Vardenafil, and Avanafil.
  • Riociguat: This substance is a soluble Guanylate Cyclase (sGC) stimulator.
  • Other Organic Nitrates: Coadministration with other nitrate or nitric oxide donor medications is prohibited.

Other Documented Interactions

Interactions that require caution or specific management are officially documented for other classes of medicines:

  • Other Blood Pressure Lowering Agents: The concurrent use of Imdex with other antihypertensive medications, such as beta-blockers, calcium channel blockers, or general vasodilators, may lead to an additive reduction in blood pressure. Agents like Tricyclic Antidepressants and Neuroleptics may also potentiate this effect.
  • Dihydroergotamine: Official documentation states that concomitant use may increase the blood level of Dihydroergotamine and its associated effects.
  • Alcohol (Ethanol): The consumption of alcohol may potentiate the blood pressure lowering effect of Isosorbide Mononitrate and increase the risk of associated side effects, such as dizziness.

Timing Restrictions

Specific regulatory constraints exist for the safe administration of nitrates after the use of a PDE5 inhibitor. For instance, a waiting period of at least 24 to 48 hours is generally required before administering any nitrate following the last dose of certain PDE5 inhibitors.

Mechanism of Action

Imdex (Isosorbide Mononitrate) exerts its physiological effects by engaging a targeted molecular cascade to modulate vascular tone and the total circulatory load on the heart. The mechanism is entirely dependent on its action as a Nitric Oxide (NO) donor and the resulting systemic changes.

The Nitric Oxide-cGMP Signaling Cascade

The drug initiates its action by releasing the signaling molecule Nitric Oxide (NO), which diffuses into vascular smooth muscle cells. NO activates the enzyme Soluble Guanylate Cyclase (sGC), triggering an increase in the second messenger, cyclic Guanosine Monophosphate (cGMP). This cascade leads to the relaxation of the smooth muscle surrounding blood vessels, causing them to widen (vasodilation).

Adjustment of Cardiac Preload via Systemic Circulation Changes

The resulting vasodilation is significantly more pronounced in the venous circulation than the arterial system, causing blood to pool in the peripheral veins. This change in volume distribution directly reduces the volume of blood returning to the heart (preload). This primary physiological consequence causes the heart to work against a reduced load, which results in a net decrease in myocardial oxygen requirement.

Constraint: Mechanism Vulnerability to Tolerance

The mechanism is subject to the limitation of nitrate tolerance, a physiological change resulting in a rapid blunting of the pharmacodynamic effect upon sustained exposure. This loss of sensitivity arises potentially from altered smooth muscle receptor response or a depletion of necessary cellular cofactors, which constrains the consistency of the vascular relaxation response.

Dosage and Administration Information

How to Use Imdex

The usage of Imdex (Isosorbide Mononitrate Extended-Release) is structured to ensure the necessary once-daily administration while avoiding pharmacological tolerance. The medicine is for oral administration as a controlled- or extended-release tablet. This sustained-action design requires the tablet to be swallowed whole with fluid and must not be crushed, chewed, or split, as doing so compromises the release mechanism.

Official Dosing Principles

Treatment typically begins with a starting dose of 30 mg or 60 mg once daily, usually in the morning on arising. The dosage may be subsequently adjusted to a maintenance range of 30 mg to 120 mg once daily, with a maximum dose up to 240 mg. This morning administration schedule is a critical procedural condition to establish a daily nitrate-free interval of at least 12 to 14 hours. This break in drug action is essential for preventing the development of drug tolerance, a known issue with chronic nitrate therapy.

Use Patterns and Adjustments

Imdex is intended for long-term prophylactic use. Administration instructions permit the tablet to be taken with or without food. For specific populations, starting older adults at the low end of the dosing range is recommended. Furthermore, the safety and effectiveness of the medication in the pediatric population are not established. If therapy must be discontinued, the dosage and frequency are required to be tapered gradually rather than stopped suddenly.

Recent Clinical Evidence

Research evidence / Overview of studies for Imdex

Evidence for Preventing Chronic Chest Discomfort (Stable Angina)

The foundational research for Imdex, whose active ingredient is Isosorbide Mononitrate, was conducted in the context of stable angina. This research primarily relies on Randomized Controlled Trials (RCTs) and systematic reviews. These trials were designed to explore how outcomes related to physical discomfort and activity level change over defined time intervals.

The studies monitored outcomes reflecting daily functioning, specifically measuring the total time an individual could sustain exercise before experiencing symptoms. Research also examined the overall frequency of anginal discomfort. Studies tracked changes in symptoms reported by the observed populations during the short-term study period, typically lasting only a few weeks.

Studies Supporting Formulation and Delivery

Research included bioequivalence trials to determine whether the active ingredient is released consistently into the bloodstream over 24 hours. These studies primarily involved controlled trials conducted in normal healthy volunteers. Research examined how the body handles the medicine, measuring the rate and total amount of the drug absorbed.

Studies reported predictable and consistent rates of absorption and delivery of the medicine. Data show patterns related to maintaining sustained drug levels over a full day. These findings describe the sustained drug exposure provided by the extended-release formulation. This research, however, does not provide any information regarding clinical suitability or long-term safety; it only confirms the technical performance of the tablet itself.

Key Limitations and Areas of Research Uncertainty

The body of research on Imdex includes certain limitations. The results apply only to the specific populations studied, and the follow-up durations were limited in many of the core efficacy trials. The primary focus of the research was on symptom patterns and functional measures (like exercise time), not on whether the medication influences the progression of the disease or prevents major cardiovascular events. Furthermore, a critical research gap relates to nitrate tolerance, where the drug's activity may diminish with continuous, uninterrupted presence.

Key Studies & References

  1. Comparative pharmacokinetics and bioavailability of immediate-release and extended-release formulations of isosorbide-5-mononitrate: a review.
  2. Guideline for the Management of Patients With Chronic Coronary Disease (Example of major clinical guideline)

Frequently Asked Questions (FAQ)

Common questions about Imdex (FAQ)

Q: Is Imdex safe to use with birth control pills?

Official drug interaction reports detail many interactions for Imdex, but typically do not list common oral contraceptives as a major or moderate interaction that requires dosage modification or avoidance. Regulatory labels highlight interactions that primarily affect blood pressure.

Q: Does Imdex interact with common supplements like Vitamin D or fish oil?

Regulatory information primarily focuses on drug-drug interactions. Standard product information does not typically list common non-pharmacological supplements like Vitamin D or fish oil as having a major or moderate interaction with Imdex.

Q: What is the long-term safety profile of Imdex?

While the core clinical trials used for approval were often short-term, regulatory documents advise that for patients taking the medicine for an extended period, the healthcare provider may check progress at regular visits. This helps ensure the medicine is working properly and allows for continued monitoring of the patient's condition and any possible changes over time.

Q: Is it normal to feel slightly dizzy when starting Imdex?

Dizziness is listed as a common side effect in official product information. This effect is described as being related to the medicine's action on blood vessels. Like headaches, this feeling is most likely to be seen when starting treatment or after a change in dose.

Q: What happens if I forget to take a dose of Imdex?

Regulatory guidance describes that if a dose is missed, it can be taken as soon as it is remembered. However, if the time is close to the next scheduled dose, regulatory information indicates the missed dose should be skipped to maintain the proper schedule. Official instructions advise against taking extra medicine to compensate for a missed dose.

Q: Is it safe to drink alcohol in moderation while on Imdex?

Official information warns that consuming alcohol (ethanol) may have an additive effect in lowering blood pressure when combined with Imdex. This interaction can increase the risk of side effects such as headache, dizziness, and lightheadedness. Official documents advise caution regarding this combination.

Q: Does Imdex change my mood or personality?

Comprehensive side effect listings in regulatory documents have included some neurological or psychiatric effects, although they are uncommon. Specifically, reactions such as insomnia, anxiety, and confusion have been reported.

Q: Does Imdex cause weight gain or weight loss?

Changes in body weight are not listed as common side effects. However, regulatory side effect listings have infrequently reported changes in appetite, such as anorexia, and occasionally decreased weight among the less common adverse reactions.

Q: Can people with diabetes use Imdex?

Diabetes is not listed in regulatory documents as an absolute reason to avoid using Imdex. However, caution is generally advised for all patients susceptible to low blood pressure or fluid loss, as these conditions may require careful management when using Imdex.

Q: Can Imdex make me feel tired or drowsy?

Official regulatory documents list dizziness and fatigue or unusual weakness as possible side effects. Because of the potential for these effects, patient counseling information advises caution when driving or operating machinery until the patient knows how the medicine affects them.

Q: Does Imdex cause sleep problems like insomnia?

Yes, sleep problems are addressed in official documentation, as insomnia (difficulty sleeping) is reported as an infrequent or uncommon adverse reaction associated with the use of this medicine.

Q: Can Imdex be taken on an empty stomach?

Yes. The official regulatory administration instructions clearly state that Imdex can be taken with or without food.

Q: How long does it usually take for Imdex to start working?

Imdex is designed as an extended-release formulation to be a long-acting medicine for prevention. Because its onset of action is slow, regulatory documents specify that this medicine is not indicated for use in treating a sudden, acute episode of chest discomfort.

Q: Do I need to get blood tests while taking Imdex?

Regulatory documents describe that if the medicine is taken for a long duration, the healthcare provider may monitor a patient’s progress during regular visits. As part of this monitoring, blood tests may be used to check for unwanted effects or to evaluate the patient's condition.

Q: Can I use Imdex if I am lactose intolerant?

The official package insert, which lists all components of the tablet, notes that the list of inactive ingredients for the Imdex tablet formulation includes lactose monohydrate.

Q: Where can I find the official research studies about Imdex?

Official information regarding clinical research trials can be found on public registries. For studies in the United States, this includes the ClinicalTrials.gov registry, which is a service provided by the National Institutes of Health (NIH).

Q: What is the typical duration of treatment with Imdex?

The drug is indicated for the long-term prophylactic (preventative) management of chronic chest discomfort. Regulatory documents do not define a specific maximum duration but do advise that treatment should be tapered gradually upon discontinuation.

Q: What are the signs of an overdose of Imdex?

Official information describes that an overdose can lead to severe side effects resulting from widened blood vessels and critically low blood pressure. Signs can include a persistent throbbing headache, confusion, vertigo, palpitations, nausea, vomiting, and fainting (syncope).

Q: Is there a generic version of Imdex available?

Yes. According to official drug listings, the active ingredient, Isosorbide Mononitrate, is available in a generic version.

Q: Does Imdex affect fertility?

Regulatory reviews, based on studies conducted in animals, did not show adverse effects on fertility when Isosorbide Mononitrate was administered to male and female rats at doses significantly higher than the maximum human dose.

How should Imdex be stored and disposed of?

The storage and disposal instructions for Imdex (Isosorbide Mononitrate Extended-Release Tablets) are defined by official regulatory labeling to ensure product stability.

Storage Conditions

Requirement Official Instruction
Temperature Store at controlled room temperature (20 C to 25 C).
Protection Keep away from excessive moisture, heat, and direct light. Do not freeze the medicine.
Container Dispense in a tight container. Do not use if the original packaging is broken or torn.
Child Safety Keep the medicine out of the reach and sight of children.

Disposal Instructions

Official labeling requires that outdated medicine or any portion of the product no longer needed must be discarded. Patients are instructed to consult a healthcare professional, such as a pharmacist or doctor, for guidance on the proper and safe method for disposing of any unused medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Imdex found in:

A-Z Index: